Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Ter Arkh ; 95(8): 664-669, 2023 Oct 11.
Article Ru | MEDLINE | ID: mdl-38158902

BACKGROUND: The problem of recurrent urinary tract infections (UTI) in patients with type 2 diabetes mellitus (DM 2) is relevant, especially when there is a combination of predisposing factors, such as female gender, history of UTI episodes, and therapy with sodium glucose cotransporter type 2 (SGLT-2) inhibitors, and the choice of effective and safe means could cause some difficulties, including ina terms of the burden of antibiotic resistance. AIM: To evaluate the effectiveness and safety of the phytoproduct Canephron® N for the prevention of exacerbations of recurrent cystitis and the effect on metabolic parameters in patients with type 2 diabetes taking SGLT-2 inhibitors. MATERIALS AND METHODS: Prospective, randomized, open, parallel group study in 60 women. The main group took the drug Canephron® N for 3 months. The main parameters for evaluating were the frequency of recurrence of cystitis, level of albuminuria and LDL-cholesterol peroxidation product - malondialdehyde. RESULTS: Within 3 months of taking Canephron® N, exacerbations of chronic cystitis were diagnosed 2 times less often, a decrease in albuminuria was found in the form of an increase in the proportion of patients with an optimal level of albuminuria by 20%, a 50% reduction in the frequency of the initial increase in albuminuria, and the absence of moderate albuminuria in all patients at the end of course of therapy. A decrease in the level of MDA by 1.4 times was noted (p=0.019). CONCLUSION: Thus, the herbal drug Canephron® N can be used for accompanying therapy and prophylactic treatment in patients with recurrent cystitis on the background of DM 2, taking SGLT-2 inhibitors. The course of therapy should last at least 3 months.


Cystitis , Diabetes Mellitus, Type 2 , Sodium-Glucose Transporter 2 Inhibitors , Urinary Tract Infections , Humans , Female , Prospective Studies , Albuminuria , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Cystitis/diagnosis , Cystitis/drug therapy , Cystitis/complications , Urinary Tract Infections/diagnosis , Urinary Tract Infections/drug therapy
2.
Vavilovskii Zhurnal Genet Selektsii ; 27(5): 522-529, 2023 Sep.
Article En | MEDLINE | ID: mdl-37808210

One of the most common congenital metabolic disorders is familial hypercholesterolemia. Familial hypercholesterolemia is a condition caused by a type of genetic defect leading to a decreased rate of removal of low-density lipoproteins from the bloodstream and a pronounced increase in the blood level of total cholesterol. This disease leads to the early development of cardiovascular diseases of atherosclerotic etiology. Familial hypercholesterolemia is a monogenic disease that is predominantly autosomal dominant. Rare pathogenic variants in the LDLR gene are present in 75-85 % of cases with an identified molecular genetic cause of the disease, and variants in other genes (APOB, PCSK9, LDLRAP1, ABCG5, ABCG8, and others) occur at a frequency of < 5 % in this group of patients. A negative result of genetic screening for pathogenic variants in genes of the low-density lipoprotein receptor and its ligands does not rule out a diagnosis of familial hypercholesterolemia. In 20-40 % of cases, molecular genetic testing fails to detect changes in the above genes. The aim of this work was to search for new genes associated with the familial hypercholesterolemia phenotype by modern high-tech methods of sequencing and machine learning. On the basis of a group of patients with familial hypercholesterolemia (enrolled according to the Dutch Lipid Clinic Network Criteria and including cases confirmed by molecular genetic analysis), decision trees were constructed, which made it possible to identify cases in the study population that require additional molecular genetic analysis. Five probands were identified as having the severest familial hypercholesterolemia without pathogenic variants in the studied genes and were analyzed by whole-genome sequencing on the HiSeq 1500 platform (Illumina). The whole-genome sequencing revealed rare variants in three out of five analyzed patients: a heterozygous variant (rs760657350) located in a splicing acceptor site in the PLD1 gene (c.2430-1G>A), a previously undescribed single-nucleotide deletion in the SIDT1 gene [c.2426del (p.Leu809CysfsTer2)], new missense variant c.10313C>G (p.Pro3438Arg) in the LRP1B gene, and single-nucleotide deletion variant rs753876598 [c.165del (p.Ser56AlafsTer11)] in the CETP gene. All these variants were found for the first time in patients with a clinical diagnosis of familial hypercholesterolemia. Variants were identified that may influence the formation of the familial hypercholesterolemia phenotype.

3.
Anesteziol Reanimatol ; (1): 29-32, 2011.
Article Ru | MEDLINE | ID: mdl-21510064

A brief historical overview of the stages of development of outpatient surgery and anesthesiology is provided. It displays features of pre-selection and evaluation of patients for pediatric ambulatory surgery, the relation to the problems of preoperative fasting, anesthesia with concomitant diseases, the relative and absolute contraindications to outpatient surgeries in children. The research discusses the need and form of administration of sedative drugs in premedication in children of different ages, their influence on the recovery time after anesthesia. Compares methods of induction and maintenance of anesthesia, the possible use of volatile and intravenous anesthetics in ambulatory surgery in children, the advantages and disadvantages of given methods, as well as options for their combination with regional blocks. Pays attention to the postoperative analgesia and control of postoperative nausea and vomiting, consider their side effects.


Ambulatory Care/methods , Ambulatory Surgical Procedures/methods , Anesthesia, Conduction/methods , Anesthesia, General/methods , Anesthesia, Conduction/adverse effects , Anesthesia, General/adverse effects , Child , Humans
4.
Khirurgiia (Mosk) ; (4): 4-8, 1996.
Article Ru | MEDLINE | ID: mdl-8926665

On the basis of experience in the treatment of 2339 patients with chemical burns of the esophagus the authors hold that, despite its traumatic character, early prophylactic bougienage is the method of choice in the prevention of cicatricial esophageal strictures. The method has become more effective today because the aggressive properties of cauterizing agents have been significantly reduced in the recent decades. The use of modern fiberoptics has greatly widened the diagnostic possibilities of endoscopy. The above circumstances have made it possible to develop and introduce into clinical practice a new differential approach to the diagnosis and treatment of chemical burns of the esophagus in children. This complex method allows, with much probability, to differentiate Degrees II and III burns in the early periods and thus free a large group of patients with Degree II esophageal burn from needless bougienage. The method leads practically to 100% prevention of stenoses and complete restoration of the organ function, reduces markedly the period of hospitalization of the patients, and allows outpatients treatment in 42% cases.


Burns, Chemical/therapy , Dilatation , Esophageal Stenosis/prevention & control , Esophagus/injuries , Burns, Chemical/complications , Burns, Chemical/pathology , Child, Preschool , Esophageal Stenosis/etiology , Esophagoscopy , Esophagus/pathology , Humans , Infant , Retrospective Studies , Severity of Illness Index
...